Table 1.
Patient Characteristics
| Variable | HCQ alone (N=8) | HCQ + Erlotinib (N=19) |
|---|---|---|
| Age in years, median (range) | 61 (48–76) | 65 (27–73) |
| Sex, n (%) | ||
| Female | 5 (63) | 9 (47) |
| Male | 3 (38) | 10 (53) |
| Race, n (%) | ||
| White | 7 (88) | 16 (84) |
| Asian | 1 (13) | 2 (11) |
| Other | - | 1 (5) |
| Baseline PS, n (%) | ||
| 0 | 3 (38) | 9 (47) |
| 1 | 5 (63) | 8 (42) |
| 2 | - | 2 (11) |
| Smoking status, n (%) | ||
| Never | 5 (63) | 10 (53) |
| Former | 1 (13) | 9 (47) |
| Current | 2 (25) | - |
| Histology, n (%) | ||
| Adenocarcinoma | 8 (100) | 19 (100) |
| EGFR mutation status, n (%) | ||
| Mutant: Exon 19 del | 4 (50) | 9 (47) |
| Mutant: L858R | 1 (13) | 2 (11) |
| Mutant: other | 1 (13) | 3 (16) |
| Wild-type | 2 (25) | 3 (16) |
| Unknown | - | 2 (11) |
| Number of prior regimens, n (%) | ||
| 1 | 1 (13) | 3 (16) |
| 2 | 4 (50) | 6 (32) |
| ≥3 | 3 (38) | 10 (53) |
| Last prior therapy, n (%) | ||
| EGFR TKI | 6 (75) | 10 (53) |
| Other | 3 (38) | 9 (47) |